ABIOMED, Inc. (ABMD) Given Consensus Rating of “Buy” by Brokerages

ABIOMED, Inc. (NASDAQ:ABMD) has earned a consensus recommendation of “Buy” from the eleven analysts that are presently covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $272.33.

A number of research analysts have recently commented on ABMD shares. BidaskClub cut ABIOMED from a “buy” rating to a “hold” rating in a research report on Tuesday, December 12th. BTIG Research cut ABIOMED from a “buy” rating to a “neutral” rating in a research report on Monday, October 16th. Jefferies Group upped their price target on ABIOMED to $250.00 and gave the company a “buy” rating in a research report on Friday, January 12th. Zacks Investment Research raised ABIOMED from a “sell” rating to a “buy” rating and set a $203.00 price target on the stock in a research report on Monday, October 30th. Finally, Leerink Swann upped their price target on ABIOMED to $300.00 and gave the company an “outperform” rating in a research report on Friday, February 2nd.

ABIOMED (NASDAQ ABMD) opened at $229.50 on Friday. ABIOMED has a 1 year low of $107.33 and a 1 year high of $255.42. The company has a market capitalization of $10,583.29, a price-to-earnings ratio of 115.91, a PEG ratio of 3.17 and a beta of 0.36.

ABIOMED (NASDAQ:ABMD) last issued its quarterly earnings results on Thursday, February 1st. The medical equipment provider reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.50 by $0.20. ABIOMED had a return on equity of 15.54% and a net margin of 16.58%. The firm had revenue of $154.00 million for the quarter, compared to analysts’ expectations of $154.00 million. During the same quarter in the prior year, the firm earned $0.34 EPS. The business’s revenue for the quarter was up 34.9% compared to the same quarter last year. analysts predict that ABIOMED will post 2.39 earnings per share for the current year.

Institutional investors and hedge funds have recently modified their holdings of the stock. Crow Point Partners LLC purchased a new stake in ABIOMED during the 4th quarter worth about $120,000. Cerebellum GP LLC purchased a new stake in ABIOMED during the 4th quarter worth about $127,000. SeaCrest Wealth Management LLC purchased a new stake in ABIOMED during the 4th quarter worth about $183,000. Rehmann Capital Advisory Group purchased a new stake in ABIOMED during the 3rd quarter worth about $202,000. Finally, Sigma Planning Corp purchased a new stake in ABIOMED during the 3rd quarter worth about $206,000. 90.65% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “ABIOMED, Inc. (ABMD) Given Consensus Rating of “Buy” by Brokerages” was first published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/02/09/abiomed-inc-abmd-given-consensus-rating-of-buy-by-brokerages.html.

ABIOMED Company Profile

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

Analyst Recommendations for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply